ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 915

IL-6R Inhibition Reduces Activation Of Different Peripheral Memory B Cell Subsets In RA

Zafar Mahmood1, Khalid Muhammad1, Marc Schmalzing2, Petra Roll3, Kathrina Eckert1, Thomas Dörner4 and Hans-Peter Tony5, 1Rheumatology and Clinical Immunology, University of Würzburg, Würzburg, Germany, 2Rheumatology/Clinical Immunology, University Hospital Würzburg, Würzburg, Germany, 3Rheumatology and Clinical immunology, University of Würzburg, Würzburg, Germany, 4CC12, Dept. Medicine/Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany, 5Rheumatology/Clinical Immunology, University of Würzburg, Würzburg, Germany

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: B cells, IL-6, Rheumatoid arthritis (RA), states of activation and tocilizumab

  • Tweet
  • Email
  • Print
Session Information

Title: B cells in Human and Animal Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Enhanced B cell activity has been proposed as part of the pathogenesis of rheumatoid arthritis also based on the clinical experiences obtained by B cell targeted therapies able to modulate memory B cells. Human peripheral memory B cells can be distinguished by the phenotypic expression of CD27 and IgD defining three major B cell subpopulations: CD27+IgD+ pre-switch, CD27+IgD- post-switch and CD27-IgD- double negative memory B cells. We analyzed these different memory populations in RA and under IL6R blockade.

Methods: B cells from RA patients were phenotypically analyzed by 8 color flow cytometry at baseline, week 12 and week 24 under tocilizumab (TCZ) treatment. Memory B cell subsets were defined by CD27 and isotype surface expression. B cell activation was identified by surface staining with CD95 and intracellular Ki-67 staining. Mutation frequencies of VH gene rearrangements were analyzed by single B cell RT-PCR. Statistical analysis was performed using Mann Whitney U test.

Results: The Ig receptor mutational frequency was highest in class switched CD27+/IgD- memory B cells with 6.1±0.3% compared to CD27-/IgD- (3.5±0.2%) largely containing memory-like B cells and CD27-/IgD+ pre-switch memory B cells (4.1±0.2%). The phenotypically analyzed isotype profile in RA patients (n=40) and healthy donors (n=18) revealed that the memory B cell pool was a heterogeneous population of IgA, IgG and IgM expressing cells. The CD27-/IgD- B cell memory population showed a clear dominance of IgG followed by IgA and IgM (~70%, 20% and 10% respectively), whereas CD27+IgD- class switched B cells had an equal distribution of IgA and IgG. Under IL-6R inhibition by TCZ, the distribution of Ig isotypes remained stable at week 12 and 24. Surface and intracellular staining of B cells showed a significantly higher percentage of CD95 (14.0±1.4%, p=0.016) and Ki-67 expression (3.0±0.3%, p=0.041)  in B cells of RA as compared to HD (CD95: 7.5±1.0% and Ki-67: 1.9±0.2% which was highest in post-switched memory B cells in RA (CD95: 38.4±2.1% and Ki-67: 8.1±1.0%). In post-switched memory B cells, IL-6R inhibition significantly decreased the expression of CD95 to 21.1±3.4 % and Ki-67 to 4.8±0.7% at week 12 with p=0.0004 and p=0.0081 respectively.

Conclusion: Our data suggest that the three major peripheral memory B cell populations, pre-, post-switch as well as CD27-/IgD- B cells harbour different numbers of mutations in their Ig receptors. These B cell subsets are activated in RA with enhanced CD95 and Ki-67 expression compared to healthy individuals and which can be reduced by IL-6R inhibition in vivo. The CD27-/IgD- B cell pool displays a significantly higher proportion of IgG bearing cells compared to post-switch B cells which is not modulated by IL-6R inhibition.


Disclosure:

Z. Mahmood,
None;

K. Muhammad,
None;

M. Schmalzing,
None;

P. Roll,
None;

K. Eckert,
None;

T. Dörner,
None;

H. P. Tony,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/il-6r-inhibition-reduces-activation-of-different-peripheral-memory-b-cell-subsets-in-ra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology